Carvolix SA (EPA:CVX)

France flag France · Delayed Price · Currency is EUR
3.490
-0.130 (-3.59%)
At close: Feb 27, 2026
149.29%
Market Cap 137.33M
Revenue (ttm) 5.27M
Net Income (ttm) -14.74M
Shares Out 39.35M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,103
Average Volume 132,403
Open 3.660
Previous Close 3.620
Day's Range 3.300 - 3.660
52-Week Range 1.160 - 5.220
Beta 0.79
RSI 57.14
Earnings Date Apr 24, 2026

About Carvolix

Carvolix SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 20... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2011
Employees 76
Stock Exchange Euronext Paris
Ticker Symbol CVX
Full Company Profile

Financial Performance

In 2024, Carvolix's revenue was 5.35 million, an increase of 337.09% compared to the previous year's 1.22 million. Losses were -14.74 million, -5.84% less than in 2023.

Financial Statements

News

There is no news available yet.